ReviewClinical microbiology reviews1998
Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections.
Review in Clinical microbiology reviews, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 459 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
459 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,410 citations in OpenAlex.
- How long do bacteria, fungi, protozoa, and viruses retain their replication capacity on inanimate surfaces? A systematic review examining environmental resilience versus healthcare-associated infection risk by "fomite-borne risk assessment".Clinical microbiology reviews · 2024Pooled it
- TLR4: A Potential Therapeutic Target in the Experimental Pathogenesis of Hemolytic-Uremic Syndrome.International journal of molecular sciences · 2026Article
- Article
- Genomic and phenotypic characterization of non-O157 Shiga toxin-producingMicrobiology spectrum · 2026Article
- Genotypic and phenotypic evidence of extended-spectrum β-lactamase and carbapenemase-producing shigatoxigenic and intimin-producing Escherichia coli in diarrheic calves in Bangladesh: A hidden zoonotic and public health risk.Veterinary research communications · 2026Article
- Comparative genomic analyses ofmSystems · 2026Article
- Molecular characterization of multi-drug resistance Escherichia coli O157:H7 from calf feces and cow milk in Bangladesh.Scientific reports · 2026Article
- STEC in the natural environment of Uruguay: genomic surveillance and environmental circulation in the framework of One Health.Microbiology spectrum · 2026Article
- Genomic epidemiology reveals statewide dispersal of clinical Shiga toxin-producingMicrobiology spectrum · 2026Article
- Precise virulence inactivation using a CRISPR-associated transposase for combating Enterobacteriaceae gut pathogens.Nature biomedical engineering · 2025Article
- Temporal and Spatial Profiling ofProteomes · 2025Article
- An antibiotic derivative as a new potential tool in the prevention of hemolytic uremic syndrome.iScience · 2025Article
- Shiga toxin-producing Escherichia coli plasmid diversity reveals virulence potential and control opportunities in animal hosts.Scientific reports · 2025Article
- Association ofFoods (Basel, Switzerland) · 2025Article
- Microbiota and metabolome dynamics induced by Shiga toxin-producingMicrobial cell (Graz, Austria) · 2025Article
- Shiga toxin-producingFrontiers in microbiology · 2025Article
- Article
- Virulent shiga toxin-producing Escherichia coli (STEC) O157:H7 ST11 isolated from ground beef in Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Molecular Evolutionary Analyses ofMicroorganisms · 2024Article
- Lipopolysaccharide Core Truncation in InvasiveInternational journal of molecular sciences · 2024Article
399 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since their initial recognition 20 years ago, Shiga toxin-producing Escherichia coli (STEC) strains have emerged as an important cause of serious human gastrointestinal disease, which may result in life-threatening complications such as hemolytic-uremic syndrome. Food-borne outbreaks of STEC disease appear to be increasing and, when mass-produced and mass-distributed foods are concerned, can involve large numbers of people. Development of therapeutic and preventative strategies to combat STEC disease requires a thorough understanding of the mechanisms by which STEC organisms colonize the human intestinal tract and cause local and systemic pathological changes. While our knowledge remains incomplete, recent studies have improved our understanding of these processes, particularly the complex interaction between Shiga toxins and host cells, which is central to the pathogenesis of STEC disease. In addition, several putative accessory virulence factors have been identified and partly characterized. The capacity to limit the scale and severity of STEC disease is also dependent upon rapid and sensitive diagnostic procedures for analysis of human samples and suspect vehicles. The increased application of advanced molecular technologies in clinical laboratories has significantly improved our capacity to diagnose STEC infection early in the course of disease and to detect low levels of environmental contamination. This, in turn, has created a potential window of opportunity for future therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.